1. Home
  2. PVL vs RNTX Comparison

PVL vs RNTX Comparison

Compare PVL & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Permianville Royalty Trust Trust Units

PVL

Permianville Royalty Trust Trust Units

HOLD

Current Price

$1.77

Market Cap

57.1M

Sector

Energy

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$15.80

Market Cap

65.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PVL
RNTX
Founded
2011
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
57.1M
65.3M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
PVL
RNTX
Price
$1.77
$15.80
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
39.2K
407.3K
Earning Date
03-20-2026
05-15-2026
Dividend Yield
7.43%
N/A
EPS Growth
N/A
44.16
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$26.85
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.58
$0.69
52 Week High
$2.04
$2.18

Technical Indicators

Market Signals
Indicator
PVL
RNTX
Relative Strength Index (RSI) 58.53 44.29
Support Level $1.74 $0.69
Resistance Level $1.77 $1.05
Average True Range (ATR) 0.04 0.07
MACD 0.01 0.01
Stochastic Oscillator 95.00 60.25

Price Performance

Historical Comparison
PVL
RNTX

About PVL Permianville Royalty Trust Trust Units

Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: